Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12786240 | 1.00 | OPRM1 (0.32) | OPRM1OPRL1MEN1ALDH1A1LMNA | |
| SCHEMBL4668738 | 0.74 | CHRM2 (0.45) | OPRM1OPRL1MEN1ALDH1A1LMNA | |
| SCHEMBL4647450 | 0.69 | KCNA5 (0.33) | MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL6764772 | 0.66 | PDE10A (0.36) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6764774 | 0.66 | PDE10A (0.36) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5605712 | 0.65 | CCR2 (0.36) | ALDH1A1LMNAGAA | |
| SCHEMBL5605708 | 0.63 | HCAR2 (0.39) | ALDH1A1LMNAGAA | |
| SCHEMBL337275 | 0.62 | CCR2 (0.36) | MEN1KMT2A | |
| SCHEMBL25261882 | 0.62 | CPB1 (0.34) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2120979 | 0.61 | TP53 (0.36) | MEN1ALDH1A1LMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586498-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8586498-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8481791-B2 | Homogeneous asymmetric hydrogenation process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20110065929-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110065929-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| US-7902110-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20100168440-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065929-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | HDHD5, HHAT, HACL2 | OPRM1 1129/4885OPRL1 4104/4885MEN1 2776/4885 |
| US-20100168440-A1 | Homogeneous Asymmetric Hydrogenation Process | HDHD5, HHAT, HVCN1 | OPRM1 988/4885OPRL1 3960/4885MEN1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.